<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36090762</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1092-8464</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Current treatment options in cardiovascular medicine</Title><ISOAbbreviation>Curr Treat Options Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Strategies for Cardio-Oncology Care During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>153</EndPage><MedlinePgn>137-153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11936-022-00965-2</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="UNASSIGNED">The COVID-19 pandemic has disrupted healthcare and has disproportionately affected the marginalized populations. Patients with cancer and cardiovascular disease (cardio-oncology population) are uniquely affected. In this review, we explore the current data on COVID-19 vulnerability and outcomes in these patients and discuss strategies for cardio-oncology care with a focus on healthcare innovation, health equity, and inclusion.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="UNASSIGNED">The growing evidence suggest increased morbidity and mortality from COVID-19 in patients with comorbid cancer and cardiovascular disease. Additionally, de novo cardiovascular complications such as myocarditis, myocardial infarction, arrhythmia, heart failure, and thromboembolic events have increasingly emerged, possibly due to an accentuated host immune response and cytokine release syndrome.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="UNASSIGNED">Patient-centric policies are helpful for cardio-oncology surveillance like remote monitoring, increased use of biomarker-based surveillance, imaging modalities like CT scan, and point-of-care ultrasound to minimize the exposure for high-risk patients. Abundant prior experience in cancer therapy scaffolded the repurposed use of corticosteroids, IL-6 inhibitors, and Janus kinase inhibitors in the treatment of COVID-19 infection. COVID-19 vaccine timing and dose frequency present a challenge due to overlapping toxicities and immune cell depletion in patients receiving cancer therapies. The SARS-CoV-2 pandemic laid bare social and ethnic disparities in healthcare but also steered in innovation to combat problems of patient outreach, particularly with virtual care. In the recovery phase, the backlog in cardio-oncology care, interplay of cancer therapy-related side effects, and long COVID-19 syndrome are crucial issues to address.</AbstractText><CopyrightInformation>&#xa9; The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Sonu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805 USA.</Affiliation><Identifier Source="GRID">grid.415731.5</Identifier><Identifier Source="ISNI">0000 0001 0725 1353</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manohar</LastName><ForeName>Shamitha Alisa</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA USA.</Affiliation><Identifier Source="GRID">grid.416570.1</Identifier><Identifier Source="ISNI">0000 0004 0459 1784</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rushin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805 USA.</Affiliation><Identifier Source="GRID">grid.415731.5</Identifier><Identifier Source="ISNI">0000 0001 0725 1353</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saji</LastName><ForeName>Anu Mariam</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA USA.</Affiliation><Identifier Source="GRID">grid.416570.1</Identifier><Identifier Source="ISNI">0000 0004 0459 1784</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Sourbha S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805 USA.</Affiliation><Identifier Source="GRID">grid.415731.5</Identifier><Identifier Source="ISNI">0000 0001 0725 1353</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganatra</LastName><ForeName>Sarju</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0296-6864</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805 USA.</Affiliation><Identifier Source="GRID">grid.415731.5</Identifier><Identifier Source="ISNI">0000 0001 0725 1353</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Cardiovasc Med</MedlineTA><NlmUniqueID>9815942</NlmUniqueID><ISSNLinking>1092-8464</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardio-oncology</Keyword><Keyword MajorTopicYN="N">Cardiotoxicity surveillance</Keyword><Keyword MajorTopicYN="N">Social determinants of health</Keyword><Keyword MajorTopicYN="N">Telemedicine</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Conflict of InterestSonu Abraham declares that she has no conflict of interest. Shamitha Alisa Manohar declares that she has no conflict of interest. Rushin Patel declares that he has no conflict of interest. Anu Mariam Saji declares that she has no conflict of interest. Sourbha S. Dani declares that he has no conflict of interest. Sarju Ganatra declares that he has no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>12</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36090762</ArticleId><ArticleId IdType="pmc">PMC9446588</ArticleId><ArticleId IdType="doi">10.1007/s11936-022-00965-2</ArticleId><ArticleId IdType="pii">965</ArticleId></ArticleIdList><ReferenceList><Title>References and Recommended Reading</Title><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: &#x2022;&#x2022; Of major importance</Title><Reference><Citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology. 2020;17:543&#x2013;58. doi: 10.1038/s41569-020-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335&#x2013;7. doi: 10.1016/S1470-2045(20)30096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. International Journal of Cancer. 2021;148:363&#x2013;74. doi: 10.1002/ijc.33213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33213</ArticleId><ArticleId IdType="pmc">PMC7404763</ArticleId><ArticleId IdType="pubmed">32683687</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; Ganatra S, Dani SS, Redd R, et al. Outcomes of COVID-19 in patients with a history of cancer and comorbid cardiovascular disease. J Natl Compr Canc Netw.&#xa0;2020;1:1&#x2013;10. This study demonstrates the patients with a history of both cancer and CVD are at significantly higher risk of experiencing COVID-19-associated adverse outcomes including mortality.</Citation><ArticleIdList><ArticleId IdType="pubmed">33142266</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverio A, Di Maio M, Citro R, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovascular Disorders. 2021;21:23. doi: 10.1186/s12872-020-01816-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01816-3</ArticleId><ArticleId IdType="pmc">PMC7789083</ArticleId><ArticleId IdType="pubmed">33413093</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard D, Nurmohamed NS, Kaiser Y, et al. Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. BMJ Open. 2021;11:e045482. doi: 10.1136/bmjopen-2020-045482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045482</ArticleId><ArticleId IdType="pmc">PMC7902321</ArticleId><ArticleId IdType="pubmed">33619201</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gallagher K, Shek A, Bean DM, et al. Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19. BMC Cardiovascular Disorders. 2021;21:327. doi: 10.1186/s12872-021-02137-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-021-02137-9</ArticleId><ArticleId IdType="pmc">PMC8254437</ArticleId><ArticleId IdType="pubmed">34217220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Hammond SP, Nohria A. The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer. JACC CardioOncol. 2020;2:350&#x2013;5. doi: 10.1016/j.jaccao.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7151392</ArticleId><ArticleId IdType="pubmed">32292919</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh A, Kumar AA, Jahangir E. Cardio-oncology care in the time of COVID-19 and the role of telehealth. JACC CardioOncol. 2020;2:356&#x2013;8. doi: 10.1016/j.jaccao.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7176391</ArticleId><ArticleId IdType="pubmed">32328590</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts ET, Mehrotra A. Assessment of disparities in digital access among medicare beneficiaries and implications for telemedicine. JAMA Internal Medicine. 2020;180:1386&#x2013;9. doi: 10.1001/jamainternmed.2020.2666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2666</ArticleId><ArticleId IdType="pmc">PMC7400206</ArticleId><ArticleId IdType="pubmed">32744601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam K, Lu AD, Shi Y, Covinsky KE. Assessing telemedicine unreadiness among older adults in the United States during the COVID-19 pandemic. JAMA Internal Medicine. 2020;180:1389&#x2013;91. doi: 10.1001/jamainternmed.2020.2671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2671</ArticleId><ArticleId IdType="pmc">PMC7400189</ArticleId><ArticleId IdType="pubmed">32744593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaro MV, Becker C, Miller D, Hassan IF, Scurlock C. ICU telemedicine implementation and risk-adjusted mortality differences between daytime and nighttime coverage. Chest. 2021;159:1445&#x2013;51. doi: 10.1016/j.chest.2020.10.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.10.055</ArticleId><ArticleId IdType="pubmed">33127432</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown S-A, Rhee J-W, Guha A, Rao VU. Innovation in precision cardio-oncology during the coronavirus pandemic and into a post-pandemic world. Front Cardiovasc Med.&#xa0;2020;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456950</ArticleId><ArticleId IdType="pubmed">32923460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kicska G, Litmanovich DE, Ordovas KG, et al. Statement from the North American Society for Cardiovascular Imaging on imaging strategies to reduce the scarcity of healthcare resources during the COVID-19 outbreak. The international journal of cardiovascular imaging. 2020;36:1387&#x2013;93. doi: 10.1007/s10554-020-01861-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-020-01861-1</ArticleId><ArticleId IdType="pmc">PMC7261212</ArticleId><ArticleId IdType="pubmed">32474676</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitzke D, Salgado R, Francone M, et al. Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR) The international journal of cardiovascular imaging. 2020;36:1801&#x2013;10. doi: 10.1007/s10554-020-01892-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-020-01892-8</ArticleId><ArticleId IdType="pmc">PMC7247913</ArticleId><ArticleId IdType="pubmed">32451877</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Qadir H, Nolan MT, Thavendiranathan P. Routine prophylactic cardioprotective therapy should be given to all recipients at risk of cardiotoxicity from cancer chemotherapy. Can J Cardiol. 2016;32:921&#x2013;5. doi: 10.1016/j.cjca.2016.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2016.04.010</ArticleId><ArticleId IdType="pubmed">27343746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani SS, Bagga S, Ganatra S. Editorial commentary: cardiovascular imaging in COVID-19: focus on safety, value, and clinical relevance. Trends Cardiovasc Med. 2021;31:17&#x2013;9. doi: 10.1016/j.tcm.2020.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.015</ArticleId><ArticleId IdType="pmc">PMC7834530</ArticleId><ArticleId IdType="pubmed">33161098</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarre LA, Yang EH, Cheng RK, et al. Cardiovascular care of the oncology patient during COVID-19: an expert consensus document from the ACC cardio-oncology and imaging councils. J Natl Cancer Inst. 2021;113:513&#x2013;22. doi: 10.1093/jnci/djaa177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djaa177</ArticleId><ArticleId IdType="pmc">PMC7717327</ArticleId><ArticleId IdType="pubmed">33179744</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Li X, Yuan M, et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018;9:1058. doi: 10.3389/fphar.2018.01058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01058</ArticleId><ArticleId IdType="pmc">PMC6198283</ArticleId><ArticleId IdType="pubmed">30386232</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Choi AD, Leipsic J, et al. Use of cardiac CT amidst the COVID-19 pandemic and beyond: North American perspective. J Cardiovasc Comput Tomogr. 2021;15:16&#x2013;26. doi: 10.1016/j.jcct.2020.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcct.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7661966</ArticleId><ArticleId IdType="pubmed">33248903</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi AD, Abbara S, Branch KR, et al. Society of cardiovascular computed tomography guidance for use of cardiac computed tomography amidst the COVID-19 pandemic endorsed by the American College of Cardiology. J Cardiovasc Comput Tomogr. 2020;14:101&#x2013;4. doi: 10.1016/j.jcct.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcct.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7102563</ArticleId><ArticleId IdType="pubmed">32317235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi WA, DiCarli MF, Blankstein R, et al. Multimodality cardiovascular imaging in the midst of the COVID-19 pandemic: ramping up safely to a new normal. JACC Cardiovasc Imaging. 2020;13:1615&#x2013;26. doi: 10.1016/j.jcmg.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7290215</ArticleId><ArticleId IdType="pubmed">32646721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the society for cardiovascular angiography and interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) J Am Coll Cardiol. 2020;76:1375&#x2013;84. doi: 10.1016/j.jacc.2020.04.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.039</ArticleId><ArticleId IdType="pmc">PMC7173829</ArticleId><ArticleId IdType="pubmed">32330544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurek A, Tajstra M, Gadula-Gacek E, et al. Impact of remote monitoring on long-term prognosis in heart failure patients in a real-world cohort: results from all-comers COMMIT-HF trial. J Cardiovasc Electrophysiol. 2017;28:425&#x2013;31. doi: 10.1111/jce.13174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.13174</ArticleId><ArticleId IdType="pubmed">28176442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology. American Heart Association. Heart Rhythm. 2020;17:e233&#x2013;e41. doi: 10.1016/j.hrthm.2020.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.03.028</ArticleId><ArticleId IdType="pmc">PMC7118697</ArticleId><ArticleId IdType="pubmed">32247013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayes-Genis A, Codina P, Abdul-Jawad Altisent O, et al. Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal. European Heart Journal Supplements. 2020;22:P29&#x2013;P32. doi: 10.1093/eurheartj/suaa169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/suaa169</ArticleId><ArticleId IdType="pmc">PMC7757718</ArticleId><ArticleId IdType="pubmed">33390867</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Fagih A, Al Onazi M, Al Basiri S, et al. Remotely monitored inactivity due to COVID-19 lockdowns. Potential hazard for heart failure patients. Saudi Med J 2020;41:1211&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804222</ArticleId><ArticleId IdType="pubmed">33130841</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman AJ, Clasen S, Hwang W-T, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncology 2018;4:e174519-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885859</ArticleId><ArticleId IdType="pubmed">29285538</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; Lenihan D, Carver J, Porter C, et al. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: an International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020;70(6):480&#x2013;504. 10.3322/caac.21635. This consensus document by the International Cardio-Oncology Society (ICOS) provides in&#xa0;depth guidance about how to provide cardio-oncology care during the COVID-19 pandemic.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934086</ArticleId><ArticleId IdType="pubmed">32910493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 2020;4:1178&#x2013;91. doi: 10.1002/rth2.12439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12439</ArticleId><ArticleId IdType="pmc">PMC7537137</ArticleId><ArticleId IdType="pubmed">33043231</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298:E70&#x2013;E80. doi: 10.1148/radiol.2020203557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020203557</ArticleId><ArticleId IdType="pmc">PMC7745997</ArticleId><ArticleId IdType="pubmed">33320063</ArticleId></ArticleIdList></Reference><Reference><Citation>Musikantow, Daniel R et al. &#x201c;Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza.&#x201d;&#xa0;JACC. Clinical electrophysiology&#xa0;vol. 7,9 (2021): 1120-1130. 10.1016/j.jacep.2021.02.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904279</ArticleId><ArticleId IdType="pubmed">33895107</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators I. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325:1620&#x2013;30. doi: 10.1001/jama.2021.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, de Barros ESPGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet (London, England) 2021;397:2253-63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177770</ArticleId><ArticleId IdType="pubmed">34097856</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine 2021;385:790-802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Dani SS, Shah S, et al. Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic. Trends Cardiovasc Med. 2020;30(6):315&#x2013;325. doi: 10.1016/j.tcm.2020.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.05.004</ArticleId><ArticleId IdType="pmc">PMC7255720</ArticleId><ArticleId IdType="pubmed">32474135</ArticleId></ArticleIdList></Reference><Reference><Citation>Borcherding N, Jethava Y, Vikas P. Repurposing anti-cancer drugs for COVID-19 treatment. Drug Des Devel Ther. 2020;14:5045&#x2013;5058. doi: 10.2147/DDDT.S282252.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S282252</ArticleId><ArticleId IdType="pmc">PMC7680713</ArticleId><ArticleId IdType="pubmed">33239864</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnquist C, Ryan BM, Horikawa I, Harris BT, Harris CC. Cytokine storms in cancer and COVID-19. Cancer Cell. 2020;38:598&#x2013;601. doi: 10.1016/j.ccell.2020.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.09.019</ArticleId><ArticleId IdType="pmc">PMC7531591</ArticleId><ArticleId IdType="pubmed">33038939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan A, Hakeem AR, Radhakrishnan S, Reddy MS, Rela M. The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients. Inflammopharmacology. 2021;29:91&#x2013;100. doi: 10.1007/s10787-020-00773-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00773-9</ArticleId><ArticleId IdType="pmc">PMC7648206</ArticleId><ArticleId IdType="pubmed">33159646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-&#x3ba;B pathway as a potential target for treatment of critical stage COVID-19 patients. Frontiers in Immunology. 2020;11:3446. doi: 10.3389/fimmu.2020.598444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598444</ArticleId><ArticleId IdType="pmc">PMC7759159</ArticleId><ArticleId IdType="pubmed">33362782</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini-Farsani Z, Farsani MY, Arab S, Forouzanfar F, Yadollahi M, Asgharzade S. Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways.&#xa0;Int Immunopharmacol&#xa0;2021:108071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378592</ArticleId><ArticleId IdType="pubmed">34482267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council Perspectives. J Am Coll Cardiol. 2019;74(25):3153&#x2013;3163. doi: 10.1016/j.jacc.2019.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.10.049</ArticleId><ArticleId IdType="pmc">PMC8211027</ArticleId><ArticleId IdType="pubmed">31856973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma. Circulation. 2020;142(17):1687&#x2013;1690. doi: 10.1161/CIRCULATIONAHA.120.048100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048100</ArticleId><ArticleId IdType="pubmed">33104402</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexamethasone in Hospitalized Patients with Covid-19.&#xa0;N Engl J Med&#xa0;2020;384:693-704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasin L, Navalesi P, Zangrillo A, et al. Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth. 2021;35:578&#x2013;84. doi: 10.1053/j.jvca.2020.11.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2020.11.057</ArticleId><ArticleId IdType="pmc">PMC7698829</ArticleId><ArticleId IdType="pubmed">33298370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307&#x2013;16. doi: 10.1001/jama.2020.17021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17021</ArticleId><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Belda J, A&#xf1;&#xf3;n JM, et al. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials. 2016;17:342. doi: 10.1186/s13063-016-1456-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-016-1456-4</ArticleId><ArticleId IdType="pmc">PMC4957909</ArticleId><ArticleId IdType="pubmed">27449641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298&#x2013;306. doi: 10.1001/jama.2020.16761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16761</ArticleId><ArticleId IdType="pmc">PMC7489432</ArticleId><ArticleId IdType="pubmed">32876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, Nicolau DV, Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9:763&#x2013;72. doi: 10.1016/S2213-2600(21)00160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet (London, England) 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354567</ArticleId><ArticleId IdType="pubmed">34388395</ArticleId></ArticleIdList></Reference><Reference><Citation>Interleukin-6 receptor antagonists in critically ill patients with Covid-19.&#xa0;N Engl J Med&#xa0;2021;384:1491-502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Br&#xe4;u N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503&#x2013;16. doi: 10.1056/NEJMoa2028700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2020;384:20&#x2013;30. doi: 10.1056/NEJMoa2030340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England) 2021;397:1637-45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:522&#x2013;32. doi: 10.1016/S2213-2600(21)00099-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00099-0</ArticleId><ArticleId IdType="pmc">PMC8078879</ArticleId><ArticleId IdType="pubmed">33676590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gritti G, Raimondi F, Bottazzi B, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142063</ArticleId><ArticleId IdType="pubmed">34031531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin L, Laing AG, Mu&#xf1;oz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765&#x2013;78. doi: 10.1016/S1470-2045(21)00213-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId><ArticleId IdType="pmc">PMC8078907</ArticleId><ArticleId IdType="pubmed">33930323</ArticleId></ArticleIdList></Reference><Reference><Citation>Palich R, Veyri M, Marot S, et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32:1051&#x2013;3. doi: 10.1016/j.annonc.2021.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.04.020</ArticleId><ArticleId IdType="pmc">PMC8081573</ArticleId><ArticleId IdType="pubmed">33932501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med.&#xa0;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giacomo AM, Giacobini G, Gandolfo C, Lofiego MF, Cusi MG, Maio M. Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: a successful but mindful mix. Eur J Cancer. 2021;156:119&#x2013;21. doi: 10.1016/j.ejca.2021.07.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.07.038</ArticleId><ArticleId IdType="pmc">PMC8339498</ArticleId><ArticleId IdType="pubmed">34428684</ArticleId></ArticleIdList></Reference><Reference><Citation>Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020;136:4&#x2013;6. doi: 10.1016/j.ejca.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7315961</ArticleId><ArticleId IdType="pubmed">32619884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Annals of the Rheumatic Diseases 2021:annrheumdis-2021-220781.</Citation><ArticleIdList><ArticleId IdType="pubmed">34285048</ArticleId></ArticleIdList></Reference><Reference><Citation>van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414&#x2013;22. doi: 10.1136/ard.2010.137216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.137216</ArticleId><ArticleId IdType="pubmed">21131643</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open 2020;3:e2010651-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265094</ArticleId><ArticleId IdType="pubmed">32478845</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18:313&#x2013;9. doi: 10.1038/s41571-021-00487-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-021-00487-z</ArticleId><ArticleId IdType="pmc">PMC7957448</ArticleId><ArticleId IdType="pubmed">33723371</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;z&#xfc;temiz C, Krystosek LA, Church AL, et al. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients. Radiology. 2021;300:E296&#x2013;E300. doi: 10.1148/radiol.2021210275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210275</ArticleId><ArticleId IdType="pmc">PMC7909072</ArticleId><ArticleId IdType="pubmed">33625300</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyfer V, Gutfeld O, Shamai S, Schlocker A, Merimsky O. COVID-19 vaccine-induced radiation recall phenomenon. International Journal of Radiation Oncology* Biology* Physics.&#xa0;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930806</ArticleId><ArticleId IdType="pubmed">33677050</ArticleId></ArticleIdList></Reference><Reference><Citation>Afacan E, &#xd6;&#x11f;&#xfc;t B, &#xdc;st&#xfc;n P, &#x15e;ent&#xfc;rk E, Yaz&#x131;c&#x131; O, Ad&#x131;&#x15f;en E. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine. Clinical and Experimental Dermatology;n/a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239891</ArticleId><ArticleId IdType="pubmed">34080223</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, McDowell L. Radiation recall phenomenon following COVID-19 vaccination. Int J Radiat Oncol Biol Phys.&#xa0;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267757</ArticleId><ArticleId IdType="pubmed">34153381</ArticleId></ArticleIdList></Reference><Reference><Citation>Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear.</Citation><ArticleIdList><ArticleId IdType="pubmed">34845008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med.&#xa0;2021;385:585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki Ben Zadok O, Shaul AA, Ben-Avraham B, et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients&#xa0;-&#xa0;a prospective cohort study. Eur J Heart Fail.&#xa0;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33963635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. New England Journal of Medicine. 2021;385:661&#x2013;2. doi: 10.1056/NEJMc2108861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2108861</ArticleId><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper MW, N&#xe1;poles AM, P&#xe9;rez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466&#x2013;2467. doi: 10.1001/jama.2020.8598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.8598</ArticleId><ArticleId IdType="pmc">PMC9310097</ArticleId><ArticleId IdType="pubmed">32391864</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC report: association between social vulnerability and a county&#x2019;s risk for becoming a COVID-19 hotspot &#x2014; United States, June 1&#x2013;July 25, 2020. 2020. at https://www.cdc.gov/mmwr/volumes/69/wr/mm6942a3.htm.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583500</ArticleId><ArticleId IdType="pubmed">33090977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Bakouny Z, Bhalla S, et al. Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study. Cancer Cell. 2020;38:769&#x2013;70. doi: 10.1016/j.ccell.2020.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7609043</ArticleId><ArticleId IdType="pubmed">33176161</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sadawi M, Hussain Y, Copeland-Halperin RS, et al. Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer. Am J Cardiol. 2021;147:116&#x2013;21. doi: 10.1016/j.amjcard.2021.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.02.013</ArticleId><ArticleId IdType="pmc">PMC8076074</ArticleId><ArticleId IdType="pubmed">33617819</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad P, Branch M, Asemota D, Elsayed R, Addison D, Brown S-A. Cardio-oncology preventive care: racial and ethnic disparities. Current Cardiovascular Risk Reports. 2020;14:18. doi: 10.1007/s12170-020-00650-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12170-020-00650-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R, Wysocki O, Zhou C, Calles A, Eastlake L, Ganatra S, Harrison M, Horsley L, Huddar P, Khan K, Mckenzie H. CORONET; COVID-19 in Oncology evaluatiON Tool: Use of machine learning to inform management of COVID-19 in patients with cancer.</Citation></Reference><Reference><Citation>Moazeni S, Cadeiras M, Yang EH, Deng MC, Nguyen KL. Anthracycline induced cardiotoxicity: biomarkers and &#x201c;Omics&#x201d; technology in the era of patient specific care. Clin Transl Med. 2017;6:17. doi: 10.1186/s40169-017-0148-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-017-0148-3</ArticleId><ArticleId IdType="pmc">PMC5425361</ArticleId><ArticleId IdType="pubmed">28493232</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh MN. Social Media and Cardiology. J Am Coll Cardiol. 2018;71:1044&#x2013;7. doi: 10.1016/j.jacc.2018.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.01.037</ArticleId><ArticleId IdType="pubmed">29495984</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeked&#xfc;z E, Karc&#x131;o&#x11f;lu AM, Utkan G, &#xdc;r&#xfc;n Y. A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer? Future Oncology. 2020;16:1879&#x2013;81. doi: 10.2217/fon-2020-0501.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2020-0501</ArticleId><ArticleId IdType="pmc">PMC7307743</ArticleId><ArticleId IdType="pubmed">32564611</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis S. Collins, M.D., Ph.D. NIH launches new initiative to study &#x201c;Long COVID&#x201d;. 2021; Available from: https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid.</Citation></Reference><Reference><Citation>Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer. 2021;20:76. doi: 10.1186/s12943-021-01363-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01363-1</ArticleId><ArticleId IdType="pmc">PMC8126512</ArticleId><ArticleId IdType="pubmed">34001144</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgrad Med. 2021;133:489&#x2013;507. doi: 10.1080/00325481.2020.1855921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2020.1855921</ArticleId><ArticleId IdType="pmc">PMC7784782</ArticleId><ArticleId IdType="pubmed">33245005</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G, Aneja R. Cancer as a prospective sequela of long COVID-19. Bioessays. 2021;43:e2000331. doi: 10.1002/bies.202000331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000331</ArticleId><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>